Human Genetic Predisposition for Arthrofibrosis in Total Knee Arthroplasty

Overview

About this study

The purpose of this study is to identify DNA mutations that significantly correlate with arthrofibrosis development after total knee arthroplasty and utilize these identifiable differences to build a screening tool that would allow for preventive treatment of patients at risk for arthrofibrosis after total knee arthroplasty, and use the identifiable differences to increase our understanding of the disease and develop new therapeutic entry points to treat the disease.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

All primary total knee arthroplasty patients (control group) and all patients who developed stiffness, had a MUA, or revision total knee arthroplasty for arthrofibrosis (arthrofibrosis group) between 01/2000-03/2024 for retrospective review, and all primary total knee arthroplasty patients and all arthrofibrosis patients who developed stiffness, will have a MUA, or will have a revision total knee arthroplasty for arthrofibrosis, prospectively as they come to Mayo Clinic

Exclusion Criteria:

Patients under 18, malignancy in operative extremity, presence of a condition interfering with the ability to provide informed consent.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 3/19/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Matthew Abdel, M.D.	Open for enrollment	Contact information: Emilee Andersen M.A. (507) 266-9807 Andersen.Emilee@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Matthew Abdel, M.D.

Open for enrollment

Contact information:

Emilee Andersen M.A.

(507) 266-9807

Andersen.Emilee@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials